Sandeep K. Reddy, M.D., named Chief Medical Officer at Caris Life Sciences

-- Role Further Enhances Company's Medical Leadership Capabilities

IRVING, Texas, May 30, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today that it has named Sandeep K. Reddy, M.D., as its Chief Medical Officer. Dr. Reddy most recently served as Senior Medical Director for Caris before assuming the Chief Medical Officer role. In his new capacity, Dr. Reddy will lead the company's research efforts through the Caris Research Institute™ and will guide strategy for deployment of Caris' innovative precision medicine tools in the clinical setting.

"Dr. Reddy brings a depth of clinical background and expertise that will further enhance Caris Life Sciences and its innovative technology platforms, which are fundamentally changing the way medicine is practiced," said David D. Halbert, Chairman and Chief Executive Officer of Caris Life Sciences. "His medical and strategic insights support our efforts to continue improving care for the patients we serve. I am very pleased to welcome him to this new and important role here at Caris."

As head of clinical research activities at Caris, Dr. Reddy will assume the critical role of Principal Investigator for the Caris Registry™, a multi-center, observational outcomes database of consenting patients whose tumors underwent multi-technology profiling by Caris Molecular Intelligence™. Dr. Reddy will also lead the company's efforts to actively engage and educate the broad oncology community regarding Caris' unparalleled services and capabilities. This will include education and advocacy efforts related to the company's work with the payer community.

"I am excited to accept this leadership position at the company that pioneered commercial tumor profiling more than eight years ago. Caris' approach is not only good clinical practice, leading to better patient outcomes and less suffering and pain related to ineffective therapy, but also more cost-efficient, as the expense of molecular profiling is generally much less expensive than the cost of ineffective treatment," said Dr. Reddy. "Beyond helping oncologists identify more treatment options than any other profiling service, Caris is also actively working to advance a better molecular understanding of cancer through innovative and clinically relevant research efforts."

Outside of his work with Caris, Dr. Reddy recently completed his term as Chief of Staff at Los Alamitos Medical Center in Los Alamitos, Calif., and also holds a clinical professorship of medicine at his alma mater, David Geffen School of Medicine at the University of California, Los Angeles (UCLA). He is also certified by the American Board of Medical Oncology and has actively practiced clinical oncology with a molecular profiling focus for the past 11 years.

About Caris Life Sciences

Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of precision medicine. Caris Molecular Intelligence™, the industry's first and largest tumor profiling service, provides an oncologist with the most potentially clinically actionable treatment options available to personalize care today. Using a variety of advanced and clinically-relevant technologies that assess all relevant biological components of a patient's cancer, Caris Molecular Intelligence correlates molecular data generated from a tumor with biomarker/drug associations derived from clinical cancer literature. The company is also developing a series of blood tests based on its proprietary Carisome® TOP™ platform, a revolutionary blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.carislifesciences.com.